(Q41475474)

1 October 2017

title

CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease (English)

1 reference

chronic obstructive pulmonary disease

1 October 2017

main subject

phase II clinical trial

0 references

1 reference

Stephen I Rennard

1

1 reference

1 October 2017

David C Dale

2

1 reference

1 October 2017

James F Donohue

3

1 reference

1 October 2017

Frank Kanniess

4

1 reference

1 October 2017

Helgo Magnussen

5

1 reference

1 October 2017

E Rand Sutherland

6

1 reference

1 October 2017

Henrik Watz

7

1 reference

1 October 2017

Susan Lu

8

1 reference

1 October 2017

Paul Stryszak

9

1 reference

1 October 2017

Elizabeth Rosenberg

10

1 reference

1 October 2017

Heribert Staudinger

11

1 reference

1 October 2017

language of work or name

English

0 references

publication date

1 May 2015

1 reference

American Journal of Respiratory and Critical Care Medicine

1 October 2017

published in

1 reference

1 October 2017

volume

191

1 reference

1 October 2017

issue

9

1 reference

1 October 2017

page(s)

1001-1011

1 reference

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

Chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

Neutrophils and the pathogenesis of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

Year in review 2011: asthma, chronic obstructive pulmonary disease and airway biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

Mediators of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

Neutrophils and protease/antiprotease imbalance

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

Matrix metalloproteinase-9 in lung remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

Neutrophils in chronic inflammatory airway diseases: can we target them and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

CXCR2 mediates NADPH oxidase-independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

Role of CXCR2 in cigarette smoke-induced lung inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

Standardisation of spirometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

Differential proteolytic enzyme activity in eosinophilic and neutrophilic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

Effect of sputum processing with dithiothreitol on the detection of inflammatory mediators in chronic bronchitis and bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

CXCR2 antagonists for the treatment of pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

CXCR2: From Bench to Bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

Characterization of cigarette smoke-induced inflammatory and mucus hypersecretory changes in rat lung and the role of CXCR2 ligands in mediating this effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201405-0992OC

10.1164/RCCM.201405-0992OC

21 January 2018

Identifiers

DOI

1 reference

1 October 2017

1 reference